Thursday, 18 April 2013

University of Kentucky to begin stem cell trial on patients recovering from a heart attack

The University of Kentucky (UK) announced yesterday a new, "ground breaking" stem cell trial for patients recovering after a heart attack. Purpose of the study is to examine whether autologous stem cells can heal a heart after a recent, major heart attack (Myocardial infarction).

During the clinical trial, run in collaboration with Gill Heart Institute and sponsored by Amorcyte, autologous stem cells are harvested by the bone marrow of the patients. The stem cells are then purified and injected into the heart using a catheter. Eligible for the trial is any patient that had a heart attack 9 to 11 days before having the procedure. Patients interested to enroll may be referred by their doctor or by themselves.

Since the stem cells are taken from the patients themselves, the UK researchers believe that the procedure comes with no "risk of autoimmunity concerns".

The study is blind and placebo controlled, which means that some of the patients will receive placebo treatment. However, patients in the control group will still receive care and follow-up by cardiologists and investigators.

Heart attack diagram

"This study is one of the very well designed studies to confirm the potentially beneficial effects of autologous (patients receiving their own stem cells) bone marrow stem cells in cardiac recovery after large heart attack. The study has multiple built-in precautions to maximise the potential benefit and minimise the risk from this new line of therapy. Bone marrow stem cells are a promising and novel therapy for regenerative medicine with proven safety and results suggestive of beneficial effects over the last decade, we are excited to be able to offer this therapy to our patients and be part of this study here in Kentucky" said Dr. Abdel-Latif, leader of the study

For more information about the trial please contact Tiffany Sandlin at

Amorcyte is a biomedical company focused in the development of cell therapy products for cardiovascular disease. Its lead product candidate, AMR-001, for the prevention of major adverse cardiac events following acute myocardial infarction (AMI), has already completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose.

CBS New York reports on the Amorcyte Phase 1 trial results

No comments:

Post a Comment

Please note that we dont offer any kind of medical advice. Questions requesting specific medical advice (e.g. where can I get this treatment, will this cure XXX condition, etc) will be published but most probably ignored by the administrators. :)

Note to spammers: You shall not pass. If you really want a link from us then consider making a stem cell related guest post !